Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
NCT01484015 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2018-07-18
Summary
This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.
Conditions
- Ovarian Germ Cell Tumor
- Plasma Cell Neoplasm
- Poor Prognosis Metastatic Gestational Trophoblastic Tumor
- Primary Myelofibrosis
- Adult Acute Lymphoblastic Leukemia
- Adult Acute Myeloid Leukemia
- Adult Burkitt Lymphoma
- Adult Diffuse Large Cell Lymphoma
- Adult Diffuse Mixed Cell Lymphoma
- Adult Diffuse Small Cleaved Cell Lymphoma
- Adult Hodgkin Lymphoma
- Adult Immunoblastic Large Cell Lymphoma
- Adult Lymphoblastic Lymphoma
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Breast Cancer
- Chronic Eosinophilic Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia
- Chronic Neutrophilic Leukemia
- Cutaneous T-cell Non-Hodgkin Lymphoma
- Disseminated Neuroblastoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3 Follicular Lymphoma
- Malignant Testicular Germ Cell Tumor
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Multiple Myeloma
- Mycosis Fungoides/Sezary Syndrome
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Neutropenia
- Nodal Marginal Zone B-cell Lymphoma
- Ovarian Epithelial Cancer
- Prolymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma
Interventions
- DRUG
-
cefepime hydrochloride
Given IV
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
John Williamson · Wake Forest University Health Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-02-28
- Primary Completion
- 2012-06-30
- Completion
- 2012-10-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
NCT03701841 ·Status: UNKNOWN
-
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
NCT00020865 ·Status: UNKNOWN ·Phase: PHASE3
-
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
NCT00770172 ·Status: COMPLETED ·Phase: PHASE3
-
Daptomycin in Treating Neutropenia and Fever in Patients With Cancer
NCT00335478 ·Status: COMPLETED ·Phase: PHASE2
-
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
NCT02996617 ·Status: UNKNOWN ·Phase: PHASE4
-
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
NCT01918241 ·Status: UNKNOWN ·Phase: PHASE2
-
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
NCT04101760 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
NCT00014456 ·Status: COMPLETED ·Phase: PHASE1
-
Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
NCT06293677 ·Status: RECRUITING ·Phase: PHASE4
-
Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia
NCT03846414 ·Status: UNKNOWN
-
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
NCT02956967 ·Status: COMPLETED
-
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
NCT07096479 ·Status: RECRUITING
-
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
NCT00094809 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia
NCT04910698 ·Status: COMPLETED
-
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
NCT00120705 ·Status: COMPLETED ·Phase: PHASE2
-
Profiling Neutrophil Counts in Patients on Chemotherapy
NCT02806557 ·Status: UNKNOWN
-
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
NCT04477616 ·Status: COMPLETED ·Phase: PHASE2
-
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
NCT01459653 ·Status: COMPLETED
-
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
NCT00148421 ·Status: COMPLETED ·Phase: PHASE3
-
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
NCT02728596 ·Status: COMPLETED ·Phase: NA
-
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
NCT05061654 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
NCT01813721 ·Status: COMPLETED
-
Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia
NCT02463747 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study Comparing Pegylated Filgrastim and Filgrastim in Support for Chemotherapy
NCT01285219 ·Status: COMPLETED ·Phase: PHASE3
-
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
NCT04460508 ·Status: UNKNOWN ·Phase: PHASE2